内美通治疗子宫内膜异位症的临床研究  

作　　者：江海霞[1] 

机构地区：[1]四川省安岳县妇幼保健院,四川安岳642350

出　　处：《现代妇女（医学前沿）》2015年第5期11-12,共2页Modern Women

摘　　要：目的评价内美通治疗子宫内膜异位症的临床效果及副反应。方法子宫内膜异位症患者40例，给予内美通口服，每周2次，用药1年。观察症状、子宫及异位囊肿体积改变：血清E2、CA125变化；副反应发生情况。结果治疗前26例有不同程度痛经，治疗3月后，20例诉痛经明显减轻或无痛经，治疗1年后均无痛经表现。治疗前子宫体积672．58±409．39cm3，治疗后528．32±357．66cm3，较治疗前缩小，差异有显著性（P〈0．05）。治疗前血清E2为257．47±187．62pmol／L，治疗后血清E2较治疗前略有降低，为223．49±135．69μmol／L，但差异无显著性。除月经少许改变外，未见严重副反应。结论内美通治疗子宫内膜异位症安全有效，有价格低、给药方便等特点，适合于成年妇女子宫内膜异位症的保守治疗。Objective To study the response of endometriosis to treatmentof Gestrinone acetate.Methods 40patients with endometriosis were by Gestrinone two times per every weak forlyear.Volume of uterus and en-dometriosis were measured by uhrasonography before and after thera- py：E 2 concentration in the serum were detected at the same time.Resuhs Symptoms Of dysmenorrhea were improved greatly.Volume of uterus was decreased （P 〈0.05） ,there were no significant changesof E 2 levels.Conclusion Gestrinone is to be safe effective treatment for En-dometriosis, more facilitate.

关 键 词：内美通 子宫内膜异位症 治疗 

分 类 号：Q579.13[生物学—生物化学]